Howard W. Lutnick, Chairman of the Board and Chief Executive Officer of BGC Partners, Inc. has informed the employees of the company via video that he was recently diagnosed with Non-Hodgkin’s Lymphoma.
BGC explains that Mr Lutnick’s form of cancer is highly treatable and he and his physicians expect that he will be cancer-free in four months. Mr. Lutnick’s treatment plan includes six chemotherapy treatments beginning on October 18, 2021 and running through the end of January 2022.
Mr Lutnick expects to continue to serve the company during this time.
Howard W. Lutnick said:
“I am now facing my greatest challenge since 9/11. I began chemo today for treatment of Non-Hodgkin’s Lymphoma. I shared this video with my 12,000 employees of Cantor Fitzgerald, BGC, & Newmark. Their outpouring of support and encouragement means more than they will ever know”.